Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:09:15 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:BOLT - BOLT BIOTHERAPEUTICS INC - http://www.bolt-technology.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BOLT - Q0.31.11·1.130.11.1364+0.02642.410.511331.12  1.14  1.092.03  0.8411:32:12Mar 2115 min RT 2¢

Recent Trades - Last 10 of 33
Time ETExPriceChangeVolume
11:32:12Q1.13410.02411
11:18:36Q1.13640.0264100
11:02:43Q1.1250.0153
10:28:46Q1.12940.01941
10:23:27Q1.1330.0231
10:12:18Q1.1052-0.00481
10:10:10Q1.10-0.017
10:10:10Q1.10-0.011
10:08:49Q1.12320.013217
10:08:49Q1.10-0.011

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-21 16:05U:BOLTNews ReleaseBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
2024-02-27 07:00U:BOLTNews ReleaseBolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
2023-12-21 07:30U:BOLTNews ReleasePacira Appoints Frank D. Lee as Chief Executive Officer
2023-12-05 07:00U:BOLTNews ReleaseBolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu ‚ ®
2023-11-09 16:05U:BOLTNews ReleaseBolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-07 07:00U:BOLTNews ReleaseBolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
2023-10-23 10:30U:BOLTNews ReleaseBolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
2023-10-18 07:00U:BOLTNews ReleaseBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer ¢ € ™s 2023 Annual Meeting
2023-10-17 07:00U:BOLTNews ReleaseBolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
2023-10-16 07:00U:BOLTNews ReleaseBolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
2023-09-28 07:00U:BOLTNews ReleaseBolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
2023-09-12 08:05U:BOLTNews ReleaseBolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
2023-09-05 16:15U:BOLTNews ReleaseBolt Biotherapeutics to Participate in September Investor Conferences
2023-08-07 16:10U:BOLTNews ReleaseBolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-08-03 07:30U:BOLTNews ReleaseBolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
2023-07-31 17:28U:BOLTNews ReleaseBolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
2023-05-30 08:00U:BOLTNews ReleaseBioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases
2023-05-25 17:05U:BOLTNews ReleaseBolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
2023-05-11 16:05U:BOLTNews ReleaseBolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update